Nature's TRAIL—On a Path to Cancer Immunotherapy
- 1 January 2003
- Vol. 18 (1) , 1-6
- https://doi.org/10.1016/s1074-7613(02)00502-2
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Death ReceptorsPublished by Wiley ,2002
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 2002
- Antiviral response by natural killer cells throughTRAIL gene induction by IFN-α/βEuropean Journal of Immunology, 2001
- Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingCell Death & Differentiation, 2001
- In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activityLeukemia, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995